Immunohematologic disorders

JAMA

Volumn 278, Issue 22, 1997, Pages 1982-1992

  Winkelstein, Alan ^a   Kiss, Joseph E ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGIC REACTION; AUTOIMMUNITY; CLINICAL FEATURE; FEVER; HEMOLYSIS; IMMUNE RESPONSE; LUNG INJURY; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA; THROMBOSIS;

EID: 0031453536     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.278.22.1982     Document Type: Review

References (113)

1. Frank MM. Complement: a brief review. J Allergy Clin Immunol. 1989;84:411-420.
2. Judd WJ, Barnes BA, Steiner EA, et al. The evaluation of a positive direct antiglobulin test (autocontrol) in pretransfusion testing revisited. Transfusion. 1986;26:220-224.
3. Molthan L, Reidenberg MM, Eichman MF. Positive direct Coombs test due to cephalothin. N Engl J Med. 1967;277:123-125.
4. Heddle NM, Kelton JG, Turchyn KL, et al. Hypergammaglobulinemia can be associated with a positive direct antiglobulin test, a nonreactive eluate, and no evidence of hemolysis. Transfusion. 1988;28:29-33.
5. Grindon AJ, Wilson MJ. False-positive DAT caused by variables in sample procurement. Transfusion. 1981;21:313-315.
6. Hamblin TJ, Oscier TJ, Young BJ, et al. Autoimmunity in chronic lymphocytic leukaemia. J Clin Pathol. 1986;39:713-716.
7. Identification of unexpected alloantibodies. In: Walker RH, ed. Technical Manual. Arlington, Va: American Association of Blood Banks; 1990:293-313.
8. Engelfriet CP, Overbeeke MAM, von dem Borne AEG Kr, et al. Autoimmune hemolytic anemia. Semin Hematol. 1992;29:3-12.
9. Nydegger UE, Kazatchkine MD, Miescher PA, et al. Immunopathologic and clinical features of hemolytic anemia due to cold agglutinins. Semin Hematol. 1991;28:66-77.
10. Engelfriet CP, Overbeeke MAM, Dooren MC, et al. Bioassays to determine the clinical significance of red cell alloantibodies based on Fc receptor-induced destruction of red cells sensitized by IgG. Transfusion. 1994;34:617-626.
11. Petz LD, Garratty G. Acquired Immune Hemolytic Anemias. New York, NY: Churchill Livingstone; 1980.
12. Gilliland BC, Baxter E, Evans RS. Red cell antibodies in acquired hemolytic anemia with negative antiglobulin serum tests. N Engl J Med. 1971;285: 252-256.
13. Pirofsky B. Clinical aspects of autoimmune hemolytic anemia. Semin Hematol. 1976;13:251-264.
14. Flores G, Cunningham-Rundles C, Newland AC, et al. Efficacy of intravenous immunoglobulin in the treatment of autoimmune hemolytic anemia: results in 73 patients. Am J Hematol. 1993;44:237-242.
15. Ness PM. Autoimmune hemolytic anemia. In: Brain MC, Carbone PP, ed. Current Therapy in Hematology-Oncology. Philadelphia, Pa: BC Decker; 1992:25-28.
16. Sokol RJ, Booker DJ, Stamps R, et al. The pathology of autoimmune haemolytic anemia. J Clin Pathol. 1992;45:1047-1052.
17. Pruzanski W, Shumak KH. Biologic activity of cold-reacting autoantibodies (second of two parts). N Engl J Med. 1977;297:583-589.
18. Hippe E, Jenson KB, Olesen H, et al. Chlorambucil treatment of patients with cold agglutinin syndrome. Blood. 1970;35:68-72.
19. Petz LD. Drug-induced autoimmune hemolytic anemia. Transfus Med Rev. 1993;7:242-254.
20. Garratty G. Immune cytopenias associated with antibiotics. Transfus Med Rev. 1993;7:255-267.
21. Garratty G, Nance S, Lloyd M, et al. Fatal immune hemolytic anemia due to cefotetan. Transfusion. 1992;32:269-271.
22. Dhawan M, Kiss JE, DiAddezzio NA, et al. Fatal cefotetan-induced immune hemolysis. Blood. 1993;82: 582a.
23. Bowman JM. Intrauterine transfusion. In: Anderson KC, Ness PM, eds. Scientific Basis of Transfusion Medicine: Implications for Clinical Practice. Philadelphia, Pa: WB Saunders Co; 1994; 4:403-420.
24. Judd WJ, Luban NLC, Ness PM, et al. Prenatal and perinatal immunohematology:recommendations for serologic management of the fetus, newborn infant, and obstetric patient. Transfusion. 1990;30:175-183.
25. Chitkara U, Wilkins I, Lynch L, et al. The role of sonography in assessing the severityof fetal anemia in Rh-and Kell-isoimmunized pregnancies. Obstet Gynecol. 1993;71:393-398.
26. Queenan JT, Tomai TP, Ural SH, et al. Deviation in amniotic fluid optic density of a wavelength of 450 nm in Rh-immunized pregnancies from 14 to 40 weeks of gestation: a proposal for clinic management. Am J Obstet Gynecol. 1993;168:1370-1376.
27. Fisk NC, Bennett P, Warwick RM, et al. Clinical utility of fetal RhD typing in alloimmunized pregnancies by means of polymerase chain reaction or aminocytes or chorionic villi. Am J Obstet Gynecol. 1994; 171:50-54.
28. Rübo J, Albrecht K, Lasch P, et al. High-dose intravenous immune globulin therapy for hyperbilirubinemia caused by Rh hemolytic disease. J Pediatr. 1992;121:93-97.
29. Bowman JM. Antenatal suppression of Rh allo-immunization. Clin Obstet Gynecol. 1991;34:296-303.
30. Bussel JB. Autoimmune thrombocytopenic purpura. Hematol Oncol Clin North Am. 1990;4:179-191.
31. Waters AH. Autoimmune thrombocytopenia: clinical aspects. Semin Hematol. 1992;29:18-25.
32. Kiefel V, Freitag E, Kroll H, et al. Platelet autoantibodies (IgG, IgM, IgA) against glycoproteins IIb/ IIIa and Ib/IX in patients with thrombocytopenia. Ann Hematol. 1996;72:280-285.
33. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practical guideline developed by explicit methods for the American Society of Hematology. Blood. 1996;88:3-40.
34. Schulman I. Idiopathic (immune) thrombocytopenic purpura in children: pathogenesis and treatment. Pediatr Rev. 1983;5:173-178.
35. Walker RW, Walker W. Idiopathic thrombocytopenia: initial illness and long term follow-up. Arch Dis Child. 1984;59:316-322.
36. Blanchette VS, Luke B, Andrew M, et al. A prospective, randomized trial of high-dose intravenous immune globulin G therapy, oral prednisone therapy, and no therapy in childhood acute immune thrombocytopenic purpura. J Pediatr. 1993;123:989-995.
37. Kaden BR, Rosse WF, Hauch TW. Immune thrombocytopenia in lymphoproliferative diseases. Blood. 1979;53:545-551.
38. den Ottolander GJ, Gratama JW, de Koning J. Brand A. Long-term follow-up study of 168 patients with immune thrombocytopenia: implications for therapy. Scand J Haematol. 1984;32:101-110.
39. Pizzuto J, Ambriz R. Therapeutic experience on 934 adults with idiopathic thrombocytopenic purpura: multicentric trial of cooperative Latin American Group on Hemostasis and Thrombosis. Blood. 1984; 64:1179-1183.
40. Law C, Marcaccio M, Tam P, et al. High-dose intravenous immune globulin and the response to splenectomy in patients with idiopathic thrombocytopenic purpura. N Engl J Med. 1997;336:1494-1498.
41. Bussel JB, Girariano JN, Kimberly RP, et al. IV anti-D treatment of immune thrombocytopenic purpura: analysis of efficacy, toxicity, and mechanism of effect. Blood. 1991;77:1984-1893.
42. Oksenhendler E, Seligmann M. HIV-related thrombocytopenia. Immunodefic Rev. 1990;2:221-231.
43. Gonzalez-Conejero R, Rivera J, Rosillo MC, et al. Association of autoantibodies against platelet glycoproteins Ib/IX and IIb/IIIa, and platelet-reactive anti-HIV antibodies in thrombocytopenic narcotic addicts. Br J Haematol. 1996;93:464-471.
44. Karpatkin S, Nardi MA, Hymes KB. Sequestration of antiplatelet GpIIIa antibody in rheumatoid factor immune complexes of human immunodeficiency virus 1 thrombocytopenic patients. Proc Natl Acad Sci U S A. 1995;92:2263-2267.
45. Kouri YH, Borkowsky W, Nardi M, et al. Human megakaryocytes have a CD4 molecule capable of binding human immunodeficiency virus-1. Blood. 1993;81: 2664-2670.
46. Hoxie JA. Hematologic manifestations of AIDS. In: Hoffman R, Bunz EJ, Shattil SJ, et al, eds. Hematology: Basic Principles and Practice. New York, NY: Churchill-Livingstone; 1995:2171-2200.
47. Chong BH, Du X, Berndt MC, et al. Characterization of the binding domains on platelet glycoproteins Ib-IX and IIb/IIIa complexes for the quinine/ quinidine-dependent antibodies. Blood. 1991;77:2190-2199.
48. Hackett T, Kelton JG, Powers P. Drug-induced platelet destruction. Semin Thromb Hemost. 1982;8: 116-137.
49. Warkentin TE, Kelton JG. Heparin-induced thrombocytopenia. Prog Hemost Thromb. 1991;10:1-34.
50. Warkentin TE, Kelton JG. Interaction of heparin with platelets, including heparin-induced thrombocytopenia. In: Bounameaux H, ed. Low-Molecular-Weight Heparins in Prophylaxis and Therapy of Thromboembolic Diseases. New York, NY: Marcel Dekker; 1994:75.
51. Kelton JG, Smith JW, Warkentin TE, et al. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood. 1994;83:3232-3239.
52. Warkentin TE, Hayward CPM, Boshkov LK, et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood. 1994;84:3691-3699.
53. Bussel JB, Zabusky MR, Berkowitz RL, et al. Fetal alloimmune thrombocytopenia. N Engl J Med. 1997;337:22-26.
54. 33 amino acid polymorphism in membrane glycoprotein IIIA, and are distinguishable by DNA typing. J Clin Invest. 1989;83:1778-1781.
55. Suarez CR, Anderson C. High-dose intravenous gammaglobulin (IVG) in neonatal immune thrombocytopenia. Am J Hematol. 1987;26:247-253.
56. McFarland JG, Aster RH, Bussel JB, et al. Prenatal diagnosis of neonatal alloimmune thrombocytopenia using allele-specific oligonucleotide probes. Blood. 1991;78:2276-2282.
57. Bussel JB, Berkowitz RL, Lynch L, et al. Antenatal management of alloimmune thrombocytopenia with intravenous gamma-globulin: a randomized trial of the addition of low-dose steroid to intravenous gamma-globulin. Am J Obstet Gynecol. 1996;174:1414-1423.
58. Bux J, Mueller-Eckhardt C. Autoimmune neutropenia. Semin Hematol. 1992;29:45-53.
59. Sasama K. Reports of 355 transfusion-associated deaths: 1976 through 1985. Transfusion. 1990;30:583-590.
60. Linden JV, Paul B, Dressler KP. A report of 104 transfusion errors in New York State. Transfusion. 1992;32:601-606.
61. Capon SM, Goldfinger D. Acute hemolytic transfusion reaction, a paradigm of two systemic inflammatory responses: new insights into pathophysiology and treatment. Transfusion. 1995;35:513-520.
62. Davenport RD, Strieler RM, Kunkel SL. Red cell ABO incompatibility and production of tumor necrosis factor-alpha. Br J Haematol. 1991;78:540-544.
63. Butler J, Parker D, Pillai R, et al. Systemic release of neutrophil elastase and tumor necrosis factor alpha following ABO incompatible blood transfusion. Br J Haematol. 1991;79:525-526.
64. Pineda AA, Tuswell HF, Brzic SM Jr. Delayed hemolytic transfusion reaction: an immunologic hazard of blood transfusion. Transfusion. 1978;18:1-7.
65. Kevy SV, Schmidt PJ, McGinnis MH, et al. Febrile, nonhemolytic transfusion reactions and the limited role of leukoagglutinins in their etiology. Transfusion. 1962;2:7-16.
66. Heddle NM, Klama LN, Griffin L, et al. A prospective study to identify risk factors associated transfusion reactions with acute reactions to platelet and red cell transfusions. Transfusion. 1993;33:794-797.
67. Dzik W. Is the febrile response to transfusion due to donor or recipient cytokine? Transfusion. 1992;32:594.
68. Muylle L, Joos M, Wourters E, et al. Increased tumor necrosis factor alpha, interleukin-1. and interleukin-6 levels in plasma of stored platelet concentrates: relationship between TNF alpha and IL-6 levels and febrile transfusion reactions. Transfusion. 1993;33:195-199.
69. Heddle NM, Klama LN, Singer J, et al. The role of plasma from platelet concentrates in transfusion reactions. N Engl J Med. 1994;331:625-628.
70. Aye MT, Palmer DS, Giulivi A, et al. Effect of filtration of platelet concentrates on the accumulation of cytokines and platelet release factors during storage. Transfusion. 1995;35:117-124.
71. Stephen CR, Martin RC, Bourgeois-Gavardin M. Antihistaminic drugs in treatment of nonhemolytic transfusion reactions. JAMA. 1955;152:525-529.
72. Sandler SG, Mallory D, Alamut, et al. IgA anaphylactic transfusion reactions. Transfus Med Rev. 1995;9:1-8.
73. Bjerrum OJ, Jersild C. Class-specific anti-IgA associated with severe anaphylactic transfusion reactions in a patient with pernicious anemia. Vox Sang. 1971;21:411-424.
74. Popovsky MA, Moore SB. Diagnostic and pathogenic considerations in transfusion-related acute lung injury. Transfusion. 1985;25:573-577.
75. Popovsky MA, Chaplin HC, Moore SB. Transfusion-related acute lung injury: a neglected, serious complication of hemotherapy. Transfusion. 1992;32: 589-592.
76. Anderson KC, Weinstein HJ. Transfusion-associated graft-versus-host disease. N Engl J Med. 1989; 323:15-21.
77. Thaler M, Shamuss A, Aorgad S, et al. The role of blood from HLA-homozygous donors in fatal transfusion-associated graft-versus-host disease after open heart surgery. N Engl J Med. 1989;321:25-28.
78. Klein HG, ed. Standards for Blood Banks and Transfusion Services. 17th ed. Bethesda, Md: American Association of Blood Banks; 1996.
79. Przepiorka D, LePark GF, Stovall MA, et al. Use of irradiated blood components: practice parameter. Am J Clin Pathol. 1996;106:6-11.
80. Mueller-Eckhardt C, Keefel V. High dose IgG for post-transfusion purpura-revisited. Br J Haematol. 1988;57:163-167.
81. Ehrenfort S, Kreuz W, Scharrer I, et al. Incidence of development of factor VIII and factor IX inhibitors in hemophiliacs. Lancet. 1992;339:594-598.
82. Robert SHR, Sallah S. Immunology of inhibitors to clotting factors with emphasis on FVIII. In: Silberstein LE, ed. Autoimmune Disorders of Blood. Bethesda, Md: American Association of Blood Banks; 1996:151-170.
83. Brettler DB, Forseberg AD, Levine PH, et al. The use of porcine factor VIII concentrates (Hyate: C) in the treatment of patients with inhibitor antibodies to FVIII: multicenter US experience. Arch Intern Med. 1989;149:1381-1385.
84. Sultan Y, Maisonneuve P, Kazatchkine MD, Nydegger UE. Anti-idiotypic suppression of autoantibodies to factor VIII (anti-haemophilic factor) by high-dose intravenous gammaglobulin. Lancet. 1984; 2:765-768.
85. Permpikul P, Rao LV, Rapaport SI. Functional and binding studies of the roles of prothrombin and β2-glycoprotein I in the expression of lupus anticoagulant activity. Blood. 1994;83:2878-2892.
86. Canoso RT, de Oliveira RM. Chlorpromazine-induced lupus anticoagulant anticardiolipin antibodies and lupus anticoagulant: absence of thrombosis. Am J Hematol. 1988;27:272-275.
87. Schleider MA, Nachman RL, Jaffe EA, et al. A clinical study of the lupus anticoagulant. Blood. 1976; 48:499-509.
88. Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Ann Intern Med. 1990;112:682-698.
89. Lechner K, Pabinger-Fasching I. Lupus anticoagulant and thrombosis: a study of 25 cases and review of the literature. Hemostasis. 1985;15:254-262.
90. Asherson RA, Khamashta MA, Gill A, et al. Cerebrovascular disease and antiphospholipid antibodies in systemic lupus erthematosus, lupus-like disease, and the primary antiphospholipid syndrome. Am J Med. 1989;86:391-399.
91. Galli M, Finazzi G, Barbui T. Thrombocytopenia in the antiphospholipid syndrome. Br J Haematol. 1996;93:1-5.
92. Harris EN, Asherson RA, Hughes GRV. Anti-phospholipid antibodies: autoantibodies with a difference. Annu Rev Med. 1988;39:261-271.
93. Triplett DA, Brandt JT, Musgrave KA, Orr CA. The relationship between lupus anticoagulants and antibodies to phospholipid. JAMA. 1988;259:550-554.
94. Cowchock S. Autoantibodies and pregnancy loss. N Engl J Med. 1997;337:197-198.
95. Laskin CA, Bombardier C, Hannah ME, et al. Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss. N Engl J Med. 1997;337:148-153.
96. Rosove MH, Tabsh K, Wasserstrum N, et al. Heparin therapy for pregnant women with lupus anticoagulants or anticardiolipin antibodies. Obstet Gynecol. 1990;75:630-634.
97. Mangan KF, Chikkappa G, Farley PC. T gamma cells suppress growth of erythroid colony-forming units in vitro in the pure red cell aplasia of B-cell chronic lymphocytic leukemia. J Clin Invest. 1982;70: 1148-1156.
98. Chapel H, Bunch C. Mechanisms of infections in chronic lymphocytic leukemia. Sem in Hematol. 1987; 24:291-296.
99. Kurec AS, Threatte GA, Gottlieb AJ, et al. Immunophenotypic subclassification of chronic lymphocytic leukemia (CLL). Br J Haematol. 1992;81:45-51.
100. Kay NE. Abnormal T-cell subpopulation function in CLL: excessive suppressor (T) and deficient helper (T) activity with respect to B-cell proliferation. Blood. 1981;57:418-420.
101. Vartersian ML. Biologic and clinical advances in multiple myeloma. Oncology. 1995;9:417-424.
102. Kyle RA, Greipp PR. The laboratory investigation of monoclonal gammopathies. Mayo Clin Proc. 1978;53:719-739.
103. Klein B, Zhang XG, Lu ZY, et al. Interleukin-6 in human multiple myeloma. Blood. 1995;85:863-873.
104. Kyle RA, Lust JA. Monoclonal gammopathies of undetermined significance. Semin Hematol. 1989;26: 176-200.
105. Crawford J, Cox EB, Cohen JH. Evaluation of hyperviscosity in monoclonal gammopathies. Am J Med. 1985;79:13-22.
106. Kantarjian HM, Redman JR, Keating MJ. Fludarabine phosphate therapy in other lymphoid malignancies. Semin Oncol. 1990;17(suppl 8):66-70.
107. Gertz MA, Li C-Y, Shirahama T, Kyle RA. Utility of subcutaneous fat aspiration for the diagnosis of systemic amyloidosis (immunoglobin light chain). Arch Intern Med. 1988;148:929-933.
108. Greipp PR, Kyle RA, Bowie EJW. Factor-X deficiency in amylodosis: a critical review. Am J Hematol. 1981;11:443-450.
109. Holmgren G, Ericzon BG, Groth CG, et al. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet. 1993;341:1113-1116.
110. Sipe JD. Amyloidosis. Annu Rev Biochem. 1992; 61:947-975.
111. Levo Y, Gorevic PD, Kassab JH, et al. Association between hepatitis B virus and essential mixed cryoglobulinemia. N Engl J Med. 1977;296:1501-1504.
112. Pascual M, Perrin L, Giostra E,et al. Hepatitis C virus in patients with cryoglobulinemia type II. J Infect Dis. 1990;162:569-570.
113. Ferri C, Marzo E, Longombardo G, et al. Interferon-α in mixed cryoglobulinemia patients: a randomized, crossover-controlled trial. Blood. 1993;81: 1132-1136.